SEATTLE, WA--(Marketwired - July 02, 2013) - Atossa Genetics, Inc.
), The Breast Health Company™, announced today that Michael H. Kalnoski, M.D., has joined the Company as Medical Director, a newly created position. Dr. Kalnoski's primary focus will be overseeing all operations of the Company's National Reference Laboratory for Breast Health
, including quality management from the handling of nipple aspirate fluid
specimens coming into the lab, to generating reports for doctors and patients, to developing new assays. He reports to Dr. Steven Quay, Chairman, CEO & President.
Dr. Kalnoski, a board certified pathologist, brings 10 years' experience as a medical director and medical consultant at a number of companies and institutions including the Puget Sound Institute of Pathology in Seattle, the Auburn Regional Medical Center in Auburn, Washington, the Valley General Hospital in Monroe, Washington, the Petersburg Medical Hospital in Petersburg, Alaska, and the Forks Medical Center in Forks, Washington. Earlier, Dr. Kalnoski was also a medical consultant at Hematologics Inc., Seattle, and medical director of Quest Diagnostics Inc., Seattle, and PacLab Inc., Renton, Washington.
"The nationwide marketing efforts we are undertaking for the ForeCYTE Breast Health Test are leading to greater awareness among doctors and an increasing number of samples coming to our lab on a daily basis," said Dr. Quay. "As the number of samples processed in the lab continues to grow, Dr. Kalnoski's extensive experience as a medical director and medical consultant will be invaluable in helping us operate the lab smoothly and efficiently, enabling us to achieve our ambitious growth objectives. I look forward to working with Michael during this exciting time."
"Atossa Genetics is a very innovative company that has the potential to significantly reduce the incidence of breast cancer through superior risk assessment tools and treatments," said Dr. Kalnoski. "I look forward to working with Dr. Quay and the outstanding team at Atossa and the National Reference Laboratory for Breast Health to help drive adoption of the ForeCYTE Breast Health Test through superior services at the laboratory level."
Dr. Kalnoski received his M.D. in 1997 from the Saint Louis University School of Medicine. He completed post graduate medical training at the University of Washington and is Board Certified in Hematopathology and Board Certified in anatomic and clinical pathology (AP/CP). Earlier Dr. Kalnoski attended the University of Washington and earned a bachelor's degree in chemistry. Dr. Kalnoski has co- authored 11 peer-reviewed, published articles.
He is a member of the American Medical Association, Pierce County Medical Society, the College of American Pathologists, the American Society of Clinical Pathology and a member the Washington State Medical Association.
About Atossa Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, based in Seattle, WA, is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography.
The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.
For additional information on Atossa and the ForeCYTE test, please visit www.atossagenetics.com. For additional information on the National Reference Laboratory for Breast Health, please visit www.nrlbh.com.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.